These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 37116859)
1. DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer. Wei SJ; Yang IH; Mohiuddin IS; Kshirsagar GJ; Nguyen TH; Trasti S; Maurer BJ; Kang MH Biochim Biophys Acta Gene Regul Mech; 2023 Jun; 1866(2):194939. PubMed ID: 37116859 [TBL] [Abstract][Full Text] [Related]
2. MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. Wei SJ; Nguyen TH; Yang IH; Mook DG; Makena MR; Verlekar D; Hindle A; Martinez GM; Yang S; Shimada H; Reynolds CP; Kang MH Cell Death Dis; 2020 May; 11(5):368. PubMed ID: 32409685 [TBL] [Abstract][Full Text] [Related]
3. Development of cell-based high throughput luminescence assay for drug discovery in inhibiting OCT4/DNA-PKcs and OCT4-MK2 interactions. Mohiuddin IS; Wei SJ; Yang IH; Martinez GM; Yang S; Cho EJ; Dalby KN; Kang MH Biotechnol Bioeng; 2021 May; 118(5):1987-2000. PubMed ID: 33565603 [TBL] [Abstract][Full Text] [Related]
4. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of c-myc protein by siRNA-mediated silencing of DNA-PKcs in HeLa cells. An J; Xu QZ; Sui JL; Bai B; Zhou PK Int J Cancer; 2005 Nov; 117(4):531-7. PubMed ID: 15929110 [TBL] [Abstract][Full Text] [Related]
6. DNA-dependent protein kinase catalytic subunit modulates the stability of c-Myc oncoprotein. An J; Yang DY; Xu QZ; Zhang SM; Huo YY; Shang ZF; Wang Y; Wu DC; Zhou PK Mol Cancer; 2008 Apr; 7():32. PubMed ID: 18426604 [TBL] [Abstract][Full Text] [Related]
7. Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer. Shatat MA; Gauthier B; Yoon S; Yuan E; Yang P; Narla G; Dowlati A; Lee RT Cancer Med; 2023 Apr; 12(7):8378-8387. PubMed ID: 36562288 [TBL] [Abstract][Full Text] [Related]
8. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer. Kim DW; Wu N; Kim YC; Cheng PF; Basom R; Kim D; Dunn CT; Lee AY; Kim K; Lee CS; Singh A; Gazdar AF; Harris CR; Eisenman RN; Park KS; MacPherson D Genes Dev; 2016 Jun; 30(11):1289-99. PubMed ID: 27298335 [TBL] [Abstract][Full Text] [Related]
9. Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer. Hamilton G; Stickler S; Rath B Curr Cancer Drug Targets; 2024; 24(9):930-940. PubMed ID: 38275056 [TBL] [Abstract][Full Text] [Related]
10. MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell Lung Carcinoma. Qin J; Xie F; Li C; Han N; Lu H Pathol Oncol Res; 2021; 27():1609775. PubMed ID: 34257619 [No Abstract] [Full Text] [Related]
12. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631 [TBL] [Abstract][Full Text] [Related]
13. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers. Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000 [TBL] [Abstract][Full Text] [Related]
14. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion. Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374 [TBL] [Abstract][Full Text] [Related]
15. Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer. Patel AS; Yoo S; Kong R; Sato T; Sinha A; Karam S; Bao L; Fridrikh M; Emoto K; Nudelman G; Powell CA; Beasley MB; Zhu J; Watanabe H Sci Adv; 2021 Jan; 7(5):. PubMed ID: 33514539 [TBL] [Abstract][Full Text] [Related]
16. Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. Suda K; Rozeboom L; Yu H; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR PLoS One; 2017; 12(2):e0172209. PubMed ID: 28192473 [TBL] [Abstract][Full Text] [Related]
17. MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung Cancer. Plotnik JP; Zha Z; Feng W; Lee I; Riehm J; McClure RA; Sandoval S; Uziel T; Murphy E; Lu X; Lam LT Mol Cancer Res; 2024 Aug; 22(8):689-698. PubMed ID: 38747975 [TBL] [Abstract][Full Text] [Related]
18. Myc protein expression correlates with MYC amplification in small-cell lung carcinoma. Hwang DH; Sun H; Rodig SJ; Hornick JL; Sholl LM Histopathology; 2015 Jul; 67(1):81-9. PubMed ID: 25407018 [TBL] [Abstract][Full Text] [Related]
19. Family matters: How MYC family oncogenes impact small cell lung cancer. Brägelmann J; Böhm S; Guthrie MR; Mollaoglu G; Oliver TG; Sos ML Cell Cycle; 2017 Aug; 16(16):1489-1498. PubMed ID: 28737478 [TBL] [Abstract][Full Text] [Related]
20. Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. Jull BA; Plummer HK; Schuller HM J Cancer Res Clin Oncol; 2001 Dec; 127(12):707-17. PubMed ID: 11768610 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]